Replimune Group (NASDAQ:REPL) Given “Hold” Rating at Jefferies Financial Group

Jefferies Financial Group reissued their hold rating on shares of Replimune Group (NASDAQ:REPL) in a report released on Monday morning, Marketbeat reports. Jefferies Financial Group currently has a $2.00 price objective on the stock, down from their previous price objective of $13.00.

REPL has been the topic of a number of other reports. Piper Sandler lowered Replimune Group from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Friday. Wedbush reissued a “neutral” rating and issued a $2.00 price target (down from $19.00) on shares of Replimune Group in a research note on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Replimune Group in a research note on Monday, December 29th. JPMorgan Chase & Co. reissued an “underweight” rating on shares of Replimune Group in a research note on Monday. Finally, HC Wainwright reissued a “sell” rating on shares of Replimune Group in a research note on Monday. Six investment analysts have rated the stock with a Hold rating and four have assigned a Sell rating to the company. Based on data from MarketBeat.com, Replimune Group presently has a consensus rating of “Reduce” and an average target price of $4.63.

Replimune Group Stock Down 64.3%

REPL opened at $1.70 on Monday. The company has a quick ratio of 5.60, a current ratio of 5.60 and a debt-to-equity ratio of 0.33. The firm has a market cap of $140.37 million, a P/E ratio of -0.49 and a beta of 0.74. Replimune Group has a 52 week low of $1.50 and a 52 week high of $13.24. The business’s fifty day simple moving average is $7.41 and its 200 day simple moving average is $7.94.

Replimune Group (NASDAQ:REPL) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported ($0.77) EPS for the quarter, beating analysts’ consensus estimates of ($0.85) by $0.08. As a group, equities research analysts anticipate that Replimune Group will post -2.97 EPS for the current fiscal year.

Insider Activity at Replimune Group

In other news, insider Christopher Sarchi sold 6,500 shares of the firm’s stock in a transaction dated Thursday, April 2nd. The stock was sold at an average price of $8.01, for a total value of $52,065.00. Following the transaction, the insider directly owned 151,588 shares in the company, valued at $1,214,219.88. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Replimune Group

Large investors have recently modified their holdings of the company. International Assets Investment Management LLC purchased a new position in shares of Replimune Group in the 4th quarter worth about $29,000. CWM LLC raised its holdings in shares of Replimune Group by 248.6% in the 4th quarter. CWM LLC now owns 4,047 shares of the company’s stock worth $39,000 after purchasing an additional 2,886 shares during the period. BNP Paribas Financial Markets raised its holdings in shares of Replimune Group by 37.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 6,889 shares of the company’s stock worth $64,000 after purchasing an additional 1,879 shares during the period. Raymond James Financial Inc. purchased a new stake in shares of Replimune Group during the 2nd quarter valued at about $69,000. Finally, Russell Investments Group Ltd. raised its holdings in shares of Replimune Group by 3,638.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 7,777 shares of the company’s stock valued at $33,000 after buying an additional 7,569 shares during the period. 92.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Replimune Group

Here are the key news stories impacting Replimune Group this week:

• Neutral Sentiment: Company response — Replimune’s executive chairman publicly called the FDA decision “unfair” and discussed next steps in a TV interview; management tone suggests they will contest or seek clarification with the agency. Replimune co-founder calls FDA rejection ‘unfair’
• Neutral Sentiment: Market mechanics — Trading on REPL was temporarily halted (LULD pause) during the sell-off as the market digested the CRL. (Intraday regulatory pause)
• Neutral Sentiment: Industry analysis — A PharmTech piece reviews lessons from the RP1 CRL for other developers; useful context but does not change Replimune’s immediate financials. What Pharma Developers Can Learn From RP1’s Rejection
• Negative Sentiment: Regulatory setback — The FDA issued a CRL for RP1’s Biologics License Application for advanced melanoma, delaying approval and forcing Replimune to address agency deficiencies before any potential approval. FDA Issues CRL to Replimune for RP1 BLA
• Negative Sentiment: Second CRL / program risk — Coverage notes this is a second CRL for RP1, increasing uncertainty about the regulatory path and timing for any approval or label; that uncertainty undermines near-term revenue and valuation expectations. Replimune Gets Second FDA CRL
• Negative Sentiment: Market reaction — Major outlets report REPL plunged to an all-time low on the news, with heavy trading and a dramatic drop in market value. Street sours on Replimune
• Negative Sentiment: Cost actions — Reports indicate Replimune is planning layoffs after the FDA decision, signaling management expects reduced near-term operating activity and is cutting burn. Replimune plans layoffs after FDA rejects cancer therapy
• Negative Sentiment: Analyst reaction — Multiple firms cut ratings and slashed price targets (downgrades and lower PTs from Jefferies, BMO, Wedbush, Leerink, JPMorgan, HC Wainwright, Piper and others), reflecting reduced probability of near-term upside. FDA Rejection Sparks Questions On Replimune Drug Approval Path

Replimune Group Company Profile

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.